These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7768627)

  • 21. Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine.
    Levenson VJ; Mallett CP; Hale TL
    Infect Immun; 1995 Jul; 63(7):2762-5. PubMed ID: 7790095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
    Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
    Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.
    Barman S; Koley H; Ramamurthy T; Chakrabarti MK; Shinoda S; Nair GB; Takeda Y
    Microbiol Immunol; 2013 Nov; 57(11):762-71. PubMed ID: 24033533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
    Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
    Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine potential for inactivated shigellae.
    Osorio M; Bray MD; Walker RI
    Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
    Mitra S; Chakrabarti MK; Koley H
    Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.
    Jneid B; Rouaix A; Féraudet-Tarisse C; Simon S
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008326. PubMed ID: 32463817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.
    Chitradevi ST; Kaur G; Uppalapati S; Yadav A; Singh D; Bansal A
    Cell Mol Immunol; 2015 Nov; 12(6):757-67. PubMed ID: 25640657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei.
    Van de Verg L; Herrington DA; Murphy JR; Wasserman SS; Formal SB; Levine MM
    Infect Immun; 1990 Jun; 58(6):2002-4. PubMed ID: 1692813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
    Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB
    Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
    Rui X; Xu Y; Wan H; Su G; Huang C
    Chin J Biotechnol; 1996; 12(2):89-97. PubMed ID: 8988355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on Shigella vaccines.
    Ashkenazi S; Cohen D
    Isr J Med Sci; 1994; 30(5-6):495-7. PubMed ID: 8034510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.
    Martinez-Becerra FJ; Scobey M; Harrison K; Choudhari SP; Quick AM; Joshi SB; Middaugh CR; Picking WL
    Vaccine; 2013 May; 31(24):2667-72. PubMed ID: 23602665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes.
    Kärnell A; Sweiha H; Lindberg AA
    Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
    Kotloff KL; Nataro JP; Losonsky GA; Wasserman SS; Hale TL; Taylor DN; Sadoff JC; Levine MM
    Vaccine; 1995 Nov; 13(16):1488-94. PubMed ID: 8578831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.